国际建议:影像学在风湿性多肌痛诊断与评估中的应用
该国际建议由12国30名专家组成的工作组制定,基于6个临床关键问题的系统文献综述,形成3条总体原则和7条推荐。核心结论为风湿性多肌痛(PMR)仍以临床诊断为主,影像学不用于高或低临床概率患者的确认或排除,最适用于中等验前概率患者,且不推荐用于疾病监测或结局预测。
要点
- PMR仍以临床诊断为核心,影像学不常规用于确诊或排除。
- 影像学最适用于中等验前概率(不典型表现或怀疑重叠/替代诊断)患者。
- 无单一影像 modality 被推荐为一线检查,需个体化选择。
核心结论
- PMR仍主要是临床诊断,影像学是情境驱动的辅助手段而非确诊或排除工具。
研究设计与样本
- 国际多学科工作组由12个国家30名成员组成,遵循EULAR标准操作流程。
- 基于6个临床关键问题(超声、MRI、18F-FDG PET在诊断、监测、结局预测及技术方面的作用)进行系统文献综述。
- 推荐基于证据和专家意见迭代制定直至达成共识,并通过投票评估同意程度。
主要发现
- 共制定3条总体原则和7条推荐。
- 高临床概率患者无需影像学确认PMR,低临床概率患者影像学也不能排除PMR。
- 影像学最适用于中等验前概率患者(即不典型表现或怀疑替代/重叠疾病)。
- 无单一影像学检查的准确性足以被推荐为一线检查。
- 怀疑重叠巨细胞动脉炎时应行血管影像学检查,但当前证据不支持系统性筛查亚临床血管炎。
关键数值与推荐
- 3条总体原则和7条推荐。
- 影像学选择应基于临床表现、鉴别诊断、可及性和当地专业能力个体化决定。
临床怎么用
- 对高临床概率PMR患者直接临床诊断,不常规安排影像学确认。
- 对低临床概率患者不依赖影像学排除PMR。
- 对中等验前概率(不典型表现或怀疑重叠/替代诊断)患者考虑影像学辅助。
- 怀疑巨细胞动脉炎重叠时行血管影像学检查,不进行亚临床血管炎系统筛查。
- 不将影像学用于PMR疾病监测或结局预测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The study aims to develop international recommendations for the use of imaging in the diagnosis and assessment of polymyalgia rheumatica (PMR). METHODS: An international, multidisciplinary task force of 30 members from 12 countries was convened; the European Alliance of Associations for Rheumatology standard operating procedures were followed. Six clinical key questions addressing the role of imaging (ultrasound, magnetic resonance imaging, and 18F-fluorodeoxyglucose positron emission tomography) in diagnosis, monitoring, outcome prediction, and technical aspects in PMR were the basis for a systematic literature review. Recommendations were formulated based on evidence and expert opinion and refined iteratively until consensus was achieved. The level of agreement was assessed by voting. RESULTS: Three overarching principles and 7 recommendations were developed. PMR remains primarily a clinical diagnosis. Imaging is neither required to confirm PMR in patients with a high clinical probability of the disease nor to exclude PMR in case of low clinical probability. Imaging is most useful in patients with intermediate pretest probability (ie, atypical presentations or suspected alternative/overlapping conditions). No single imaging modality demonstrated sufficient accuracy to be recommended as a first-line test; therefore, imaging should be individualised according to clinical presentation, differential diagnoses, access, and local expertise. Vascular imaging should be performed when overlap with giant cell arteritis is suspected, whereas systematic screening for subclinical vasculitis is not supported by current evidence. Utilising imaging for disease monitoring or outcome prediction is currently not recommended. CONCLUSIONS: These recommendations provide the first evidence-based guidance for the use of imaging in PMR, reinforcing clinical assessment as the cornerstone of diagnosis and positioning imaging as a context-driven adjunct.
引用
- Bond, Hysa, Konzett, et al. International recommendations for the use of imaging in the diagnosis and assessment of polymyalgia rheumatica. Ann Rheum Dis. 2026. PMID: 42946585. doi:10.1016/j.ard.2026.09.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。